C4X Discovery Holdings plc (AIM:C4XD), a healthcare services company based in United Kingdom, saw a significant share price rise of over 20% in the past couple of months on the AIM. Less-covered, ...

C4X Discovery Holdings plc (LON:C4XD) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. C4X Discovery Holdings plc operates as drug ...

22 September 2025 – C4X Discovery Holdings Ltd ("C4XD"), a pioneering Drug Discovery company, today announces the selection of a potential best-in-class pre-clinical candidate from its oral α4β7 ...

Valerio Therapeutics Annual stock financials by MarketWatch. View the latest C4X financial statements, income statements and financial ratios.

22 July 2024 - C4X Discovery Limited (“C4XD”), a pioneering drug discovery company, today provides an update on the business following its delisting from AIM earlier in the year. Clive Dix, Executive ...

LONDON (Reuters) - Britain's C4X Discovery said on Tuesday it was confident of striking partnership deals for its programmers in therapy areas such as sickle cell, cancer and inflammation, sending the ...

Manchester and London, UK, 12 June, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced the appointment of Piers Morgan as Chief Executive Officer with ...

Gene-editing specialists Horizon Discovery is to work with C4X Discovery to exploit CRISPR-Cas9 and other novel technologies to develop new oncology candidates. The two UK-based companies are among a ...

April 12 (Reuters) - Drug developer C4X Discovery C4XD.L said on Monday it has signed an exclusive licensing deal worth up to 414 million euros ($492.12 million) with French drugmaker Sanofi SASY.PA ...

LONDON (Reuters) -Drug developer C4X Discovery said on Monday it had signed an exclusive licensing deal worth up to 414 million euros ($492.12 million) with French drugmaker Sanofi to develop an oral ...